Eli Lilly is building a $5 billion manufacturing facility in Richmond, Va. It is the company’s first fully integrated facility for active pharmaceutical ingredients.
The site is also intended to support the drugmaker’s bioconjugate platform and monoclonal antibody portfolio, including antibody drug conjugates for cancer, autoimmune diseases and other conditions, according to an Sept. 16 news release from Eli Lilly.
The project is a part of Eli Lilly’s effort to expand domestic pharmaceutical manufacturing, with this being the first of four sites the company plans to announce this year. The new integrated facility is expected to be up and running within five years.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
